/4883.T
4883.T Stock - Modalis Therapeutics Corporation
Healthcare|Drug Manufacturers - Specialty & GenericJPX
$55.00+1.85%
+$1.00 (+1.85%) • Dec 24
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.4
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $60.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for 4883.T
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$54.45 – $55.55
TARGET (TP)$63.25
STOP LOSS$50.60
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.03
52W High$127.00
52W Low$52.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $40.50M | $1.10M | $342.00M |
| Gross Profit | N/A | $-731,000 | $-83,175,000 | $1.10M | $342.00M |
| Gross Margin | N/A | N/A | -205.4% | 100.0% | 100.0% |
| Operating Income | $-1,337,650,000 | $-2,370,666,000 | $-2,063,194,000 | $-1,239,444,000 | $-398,351,000 |
| Net Income | $-1,317,894,000 | $-2,391,821,000 | $-2,702,709,000 | $-738,956,000 | $-448,407,000 |
| Net Margin | N/A | N/A | -6673.4% | -67177.8% | -131.1% |
| EPS | $-28.57 | $-77.24 | $-92.85 | $-25.70 | $-17.02 |
Company Overview
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
4883.TBeat Rate
11%
Last 9 quarters
Avg Surprise
-4609.9%
EPS vs Estimate
Beats / Misses
1/8
Last 12 quarters
Latest EPS
$-10.13
Q4 2025
EPS Surprise History
Q1 24
-40883.3%
$-24.47vs$0.06
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 7, 2025 | — | $-10.13 | — | — |
Q3 2025 | Aug 7, 2025 | — | $-5.09 | — | — |
Q2 2025 | May 8, 2025 | — | $-9.02 | — | — |
Q1 2025 | Feb 12, 2025 | — | $-3.81 | — | — |
Q4 2024 | Nov 7, 2024 | — | $-6.09 | — | — |
Q3 2024 | Aug 7, 2024 | — | $-8.66 | — | — |
Q2 2024 | May 8, 2024 | — | $-13.57 | — | — |
Q1 2024 | Feb 14, 2024 | $0.06 | $-24.47 | -40883.3% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-14.50 | $-34.70 | -139.3% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-10.07 | $-16.84 | -67.2% | ✗ MISS |
Q2 2023 | May 9, 2023 | — | $-17.86 | — | — |
Q1 2023 | Feb 13, 2023 | $12.36 | $-47.72 | -486.1% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-17.21 | $-18.34 | -6.6% | ✗ MISS |
Q3 2022 | Aug 5, 2022 | $-10.01 | $-11.57 | -15.6% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-12.52 | $-15.13 | -20.8% | ✗ MISS |
Q1 2022 | Feb 14, 2022 | $-11.84 | $-19.28 | -62.8% | ✗ MISS |
Q4 2021 | Nov 5, 2021 | — | $-7.63 | — | — |
Q3 2021 | Aug 5, 2021 | — | $-6.41 | — | — |
Q2 2021 | May 6, 2021 | $-7.63 | $7.07 | +192.7% | ✓ BEAT |
Q1 2021 | Feb 12, 2021 | — | $-8.68 | — | — |
Latest News
Loading news...
Frequently Asked Questions about 4883.T
What is 4883.T's current stock price?
Modalis Therapeutics Corporation (4883.T) is currently trading at $55.00 per share. The stock has moved +1.85% today.
What is the analyst price target for 4883.T?
No analyst price targets are currently available for this stock.
What sector is Modalis Therapeutics Corporation in?
Modalis Therapeutics Corporation operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the JPX exchange.
What is 4883.T's market cap?
Modalis Therapeutics Corporation has a market capitalization of $4.23 billion, making it a mid-cap company.
Does 4883.T pay dividends?
No, Modalis Therapeutics Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare Sector206A.T
PRISM BioLab Co.,LTD
$148.00
Mkt Cap: $5.4B
2796.T
Pharmarise Holdings Corporation
$531.00
Mkt Cap: $6.0B
4539.T
Nippon Chemiphar Co., Ltd.
$1542.00
Mkt Cap: $5.6B
4576.T
D. Western Therapeutics Institute, Inc.
$93.00
Mkt Cap: $4.1B
4582.T
SymBio Pharmaceuticals Limited
$89.00
Mkt Cap: $4.3B
4586.T
MedRx Co., Ltd
$111.00
Mkt Cap: $6.4B
4597.T
Solasia Pharma K.K.
$28.00
Mkt Cap: $7.2B
4892.T
Cyfuse Biomedical K.K.
$588.00
Mkt Cap: $5.2B
7079.T
WDB coco Co., Ltd.
$2670.00
Mkt Cap: $6.4B
7980.T
Shigematsu Works Co., Ltd.
$772.00
Mkt Cap: $5.5B
Explore stocks similar to 4883.T for comparison